Literature DB >> 25544649

Potential anti-cancer drugs commonly used for other indications.

Veronika Hanusova, Lenka Skalova, Vera Kralova, Petra Matouskova1.   

Abstract

An increasing resistance of mammalian tumor cells to chemotherapy along with the severe side effects of commonly used cytostatics has raised the urgency in the search for new anti-cancer agents. Several drugs originally approved for indications other than cancer treatment have recently been found to have a cytostatic effect on cancer cells. These drugs could be expediently repurposed as anti-cancer agents, since they have already been tested for toxicity in humans and animals. The groups of newly recognized potential cytostatics discussed in this review include benzimidazole anthelmintics (albendazole, mebendazole, flubendazole), anti-hypertensive drugs (doxazosin, propranolol), psychopharmaceuticals (chlorpromazine, clomipramine) and antidiabetic drugs (metformin, pioglitazone). All these drugs have a definite potential to be used especially in combinations with other cytostatics; the chemotherapy targeting of multiple sites now represents a promising approach in cancer treatment. The present review summarizes recent information about the anti-cancer effects of selected drugs commonly used for other medical indications. Our aim is not to collect all the reported results, but to present an overview of various possibilities. Advantages, disadvantages and further perspectives regarding individual drugs are discussed and evaluated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25544649     DOI: 10.2174/1568009615666141229152812

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  21 in total

1.  Radiosynthesis of microtubule-targeted theranostic methyl N-[5-(3'-radiohalobenzoyl)-1H-benzimidazol-2-yl]carbamates.

Authors:  Zbigniew P Kortylewicz; Janina Baranowska-Kortylewicz
Journal:  J Labelled Comp Radiopharm       Date:  2018-04-29       Impact factor: 1.921

2.  Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.

Authors:  Yu-Qian Zhao; Yi-Qiong Yin; Jie Liu; Gui-Hua Wang; Jian Huang; Ling-Juan Zhu; Jin-Hui Wang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

3.  Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells.

Authors:  Jisu Jeong; Jiyeon Kim
Journal:  Front Pharmacol       Date:  2021-03-24       Impact factor: 5.810

4.  Oxibendazole inhibits prostate cancer cell growth.

Authors:  Qiaoli Chen; Yuhua Li; Xiaoyu Zhou; Runsheng Li
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

5.  Kallikrein-related peptidase 6 induces chemotherapeutic resistance by attenuating auranofin-induced cell death through activation of autophagy in gastric cancer.

Authors:  Tae Woo Kim; Seon-Jin Lee; Jong-Tae Kim; Sun Jung Kim; Jeong-Ki Min; Kwang-Hee Bae; Haiyoung Jung; Bo-Yeon Kim; Jong-Seok Lim; Young Yang; Do-Young Yoon; Yong-Kyung Choe; Hee Gu Lee
Journal:  Oncotarget       Date:  2016-12-20

6.  Metformin exhibits preventive and therapeutic efficacy against experimental cystic echinococcosis.

Authors:  Julia A Loos; Valeria A Dávila; Christian R Rodrígues; Romina Petrigh; Jorge A Zoppi; Fernando A Crocenzi; Andrea C Cumino
Journal:  PLoS Negl Trop Dis       Date:  2017-02-09

7.  Carbonyl Reduction of Flubendazole in the Human Liver: Strict Stereospecificity, Sex Difference, Low Risk of Drug Interactions.

Authors:  Vladimír Kubíček; Lenka Skálová; Adam Skarka; Věra Králová; Jana Holubová; Jana Štěpánková; Zdeněk Šubrt; Barbora Szotáková
Journal:  Front Pharmacol       Date:  2019-05-28       Impact factor: 5.810

8.  In Vitro Effects of Propranolol on T Helper Type 1 Cytokine Profile in Human Leukemic T Cells.

Authors:  Fatemeh Hajighasemi; Abbas Mirshafiey
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-04-01

9.  A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.

Authors:  Yura Lee; Kyoung Jun Bae; Hae Jung Chon; Seong Hwan Kim; Soon Ae Kim; Jiyeon Kim
Journal:  Mol Cells       Date:  2016-03-30       Impact factor: 5.034

10.  Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound.

Authors:  Jiyuan Liu; Zhen Tian; Nan Zhou; Xueying Liu; Chenyi Liao; Beilei Lei; Jianing Li; Shengyong Zhang; Hui Chen
Journal:  Oncotarget       Date:  2017-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.